COSENTYX® (Secukinumab)
1 Biologic
HCP | Axial spondyloarthirtis (axSpA)
Strategy:
The strategy behind this campaign was to emphasize the significance of approval for a single biologic, using the power of “one” as a bold and unifying narrative element. By spotlighting the number one, the campaign elevates the sense of scale and impact this advancement can have on patients’ lives, underscoring its importance in treatment progression. This approach seamlessly integrates with the existing brand identity while clearly communicating the milestone approval for nr-axSpA.
Leave Behind Emails - Desktop & Mobile
During a period when email communication played a critical role in patient engagement, we developed a series of thoughtfully structured emails designed to strengthen the connection between healthcare providers and their patients. The strategy prioritized clarity, accessibility, and relevance, ensuring that essential information was delivered in a concise, informative manner that supported both understanding and meaningful action.
Leave Behind Email - General
Leave Behind Email - DOF
Leave Behind Email - non-DOF
Digital Banners
A series of digital banners were developed to extend the campaign across web platforms. Multiple size variations were created to ensure broad placement flexibility, maximizing reach and reinforcing brand communications across diverse digital environments.
Print Materials
A series of print materials were also developed particularly for healthcare providers to introduce Cosentyx into their patients’ lives. This work included 2 variations of a leave behind and an FAQ booklet.
DOF axSpA Leave Behind - Version 1
Referrer Leave Behind - Version 2
FAQ Booklet
We developed a comprehensive, print-ready Frequently Asked Questions resource to support healthcare professionals in confidently prescribing Cosentyx. The booklet addresses common concerns, equips HCPs with clear and reassuring information, and facilitates more productive conversations with patients. By easing apprehensions and streamlining dialogue, it is designed to strengthen patient–provider engagement and help overcome potential barriers to treatment.